A 10 A new experimental model of hemolytic anemia after butoxyethanol and the study of its immunology / V. A. Chereshnev, P. V. Kosareva, E. I. Samodelkin, L. V. Sivakova // Hellenic Journal of Nuclear Medicine. - 2014. - January-April. - P7-10. - Bibliogr. : p. 10 (12 ref.) Рубрики: ЗДРАВООХРАНЕНИЕ. МЕДИЦИНСКИЕ НАУКИ Кл.слова (ненормированные): RATS - AUTOIMMUNITY BUTOXYETHANOL -- HEMOLYTIC ANEMIA Аннотация: 2-butoxyethanol (C6H14O2) is widely used in many industrial reagents; according to the in vitro data it was established that 2- butoxyethanol metabolites are strong haemolytic poisons. Ghanayem B.I., Sullivan Ch.A. (1993) investigated in vitro the effect of BE on the red blood cells of 10 species of mammals, including humans. In this study, the authors established the species specificity with regard to the development of hemolytic anemia under the effect of butoxyethanol [4]. In the context of the available data, creation of experimental model based on the introduction of animal butoxyethanol is taking place. Since the druginduced hemolytic anemia is formed at the adjacency of toxic and autoimmune forms, the study of immunology of any toxic anemia is of great interest. Objective: to develop a new experimental model of hemolytic anemia after butoxyethanol and to study its immunology. In conclusion, the proposed model of hemolytic anemia after butoxyethanol may be used in the experimental and preclinical studies. The intraperitoneal administration of butoxyethanol provokes an autoimmune response directed against own red blood cells. The intraperitoneal administration of butoxyethanol to experimental animals is accompanied by a reduction of the lymphoid tissue that corresponds to the appropriate response to stress in the central and peripheral organs of immunogenesis \\\\expert2\\nbo\\Hellenic Journal of Nuclear Medicine\\2014. P. 7-10.pdf |
N 89 Novelties in the field of autoimmunity – 1st Saint Petersburg congress of autoimmunity, the bridge between east and west / Sh. Dahan, Y. Segal, A. Watad [et al.] // Autoimmunity Reviews. - 2017. - Vol. 16. - P1175-1184 Рубрики: ЗДРАВООХРАНЕНИЕ. МЕДИЦИНСКИЕ НАУКИ Кл.слова (ненормированные): AUTOIMMUNITY -- HUMAN PAPILLOMA VIRUS -- ALZHEIMER'S DISEASE -- INTRA VENOUS IMMUNOGLOBULINS -- PARANEOPLASTIC NEUROLOGICAL SYNDROME -- SYSTEMIC LUPUS ERYTHEMATOSUS -- ANTI-PHOSPHOLIPID SYNDROME \\\\Expert2\\NBO\\Autoimmunity Reviews\\2017 V. 16 P. 1175-1184.pdf |
Antinuclear autoantibodies in healthy individuals: autoimmunity is not a synonym of autoimmune disease / I. A. Pashnina, I. M. Krivolapova, T. V. Fedotkina [et al.] // Preprints. - 2020. - 28 Oct. - Ст. 2020100591. - 27 p. Рубрики: ЗДРАВООХРАНЕНИЕ. МЕДИЦИНСКИЕ НАУКИ Аннотация: Incidence of autoimmune diseases increases. Antinuclear antibodies (ANA) testing is a critical tool for their diagnosis. However, ANA prevalence in health increased over last decades, especially among young people. ANA in health occur in low concentrations, with prevalence up to 50% in some populations, which demands a cutoff revision. The review deals with origin and probable physiological or compensatory function of ANA in health, according to the concept of immunological clearance, theory of autoimmune regulation of cell functions and the concept of functional autoantibodies. Considering ANA titers ≤1:320 as a serological marker of autoimmune diseases seems inappropriate. The role of anti-DFS70/LEDGFp75 autoantibodies is highlighted as possible anti-risk biomarker for autoimmune rheumatic disorders. ANA prevalence in health is different in various regions due to several underlying causes discussed in the review, all influencing in additive combinations according to the concept of the mosaic of autoimmunity. Not only titer, but the HEp-2 IFA staining patterns, like AC-2, is also important. Accepting autoantibodies as a kind of bioregulators, not only upper, but also lower borders of their normal range should be determined. Not only their excess, but also lack of them or “autoimmunodeficiency” could be a reason of disorders. \\\\Expert2\\NBO\\Электрон. библиотека (Отеч.периодика)\\Черешнев В. А\\Preprints 2020 Ст. 2020100591.pdf |
Antinuclear autoantibodies in healthy individuals: autoimmunity is not a synonym of autoimmune disease : doi.org/10.3390/antib10010009 / I. A. Pashnina, I. M. Krivolapova, T. V. Fedotkina [et al.] // Antibodies. - 2021. - Vol. 10, № 1. - Ст. 9 Рубрики: ЗДРАВООХРАНЕНИЕ. МЕДИЦИНСКИЕ НАУКИ Аннотация: Incidence of autoimmune diseases increases. Antinuclear antibodies (ANA) testing is a critical tool for their diagnosis. However, ANA prevalence in health increased over last decades, especially among young people. ANA in health occur in low concentrations, with prevalence up to 50% in some populations, which demands a cutoff revision. The review deals with origin and probable physiological or compensatory function of ANA in health, according to the concept of immunological clearance, theory of autoimmune regulation of cell functions and the concept of functional autoantibodies. Considering ANA titers ≤1:320 as a serological marker of autoimmune diseases seems inappropriate. The role of anti-DFS70/LEDGFp75 autoantibodies is highlighted as possible anti-risk biomarker for autoimmune rheumatic disorders. ANA prevalence in health is different in various regions due to several underlying causes discussed in the review, all influencing in additive combinations according to the concept of the mosaic of autoimmunity. Not only titer, but the HEp-2 IFA staining patterns, like AC-2, is also important. Accepting autoantibodies as a kind of bioregulators, not only upper, but also lower borders of their normal range should be determined. Not only their excess, but also lack of them or “autoimmunodeficiency” could be a reason of disorders. \\\\Expert2\\NBO\\Электрон. библиотека (Отеч.периодика)\\Черешнев В. А\\Antibodies. - 2021. - Vol. 10, № 1. - Ст. 9.pdf |
SARS-Cov-2-specific immune response and the pathogenesis of Covid-19 / E. Gusev, A. Sarapultsev, L. Solomatina, V. Chereshnev // International journal of molecular sciences. - 2022. - Vol. 23, № 3. - Ст. 1716 Рубрики: ЗДРАВООХРАНЕНИЕ. МЕДИЦИНСКИЕ НАУКИ Кл.слова (ненормированные): КОРОНАВИРУС -- COVID 19 -- AUTOIMMUNITY -- ADAPTIVE IMMUNITY -- CELLULAR STRESS -- SARS-CoV-2; Аннотация: The review aims to consolidate research findings on the molecular mechanisms and virulence and pathogenicity characteristics of coronavirus disease (COVID-19) causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and their relevance to four typical stages in the development of acute viral infection. These four stages are invasion; primary blockade of antiviral innate immunity; engagement of the virus’s protection mechanisms against the factors of adaptive immunity; and acute, long-term complications of COVID-19. The invasion stage entails the recognition of the spike protein (S) of SARS-CoV-2 target cell receptors, namely, the main receptor (angiotensin-converting enzyme 2, ACE2), its coreceptors, and potential alternative receptors. The presence of a diverse repertoire of receptors allows SARS-CoV-2 to infect various types of cells, including those not expressing ACE2. During the second stage, the majority of the polyfunctional structural, non-structural, and extra proteins SARS-CoV-2 synthesizes in infected cells are involved in the primary blockage of antiviral innate immunity. A high degree of redundancy and systemic action characterizing these pathogenic factors allows SARS-CoV-2 to overcome antiviral mechanisms at the initial stages of invasion. The third stage includes passive and active protection of the virus from factors of adaptive immunity, overcoming of the barrier function at the focus of inflammation, and generalization of SARS-CoV-2 in the body. The fourth stage is associated with the deployment of variants of acute and long-term complications of COVID-19. SARS-CoV-2’s ability to induce autoimmune and autoinflammatory pathways of tissue invasion and development of both immunosuppressive and hyperergic mechanisms of systemic inflammation is critical at this stage of infection. |